Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors
https://doi.org/10.47360/1995-4484-2020-443-446
Abstract
Immunotherapy with immune checkpoint inhibitors (ICIs) opens up new prospects in treatment of malignancies, although this novel therapy quite often results in development of immune-related adverse events (irAEs), which can limit their clinical use. IrAEs can affect almost any organ system, including the endocrine, respiratory, digestive, nervous, other organs and the skin. Most often irAEs are characterized by moderate degree of severity, but complications are fatal in 2% of patients.The nature of irAEs significantly differs from the adverse reactions associated with use of standard chemotherapeutic agents, which usually cause immunosuppression (due to neutropenia). Of particular interest to clinicians are rheumatic irAEs, which can occur at any time after treatment and tend to persist even after ICIs discontinuation. This review analyzes the prevalence, clinical characteristics, and approaches to treatment of rheumatic irAEs.
About the Authors
I. V. Menshikova
I.M. Sechenov First Moscow State Medical University, MOH (Sechenov University)
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2 Moscow 119991
V. V. Strogonova
I.M. Sechenov First Moscow State Medical University, MOH (Sechenov University)
Russian Federation
8, Trubetskaya St., Build. 2 Moscow 119991
Russian Federation
8, Trubetskaya St., Build. 2 Moscow 119991
References
1. Kostine M, Finckh A, Bingham CO III, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors [published online April 23, 2020]. Ann Rheum Dis. doi:10.1136/annrheumdis-2020-217139
2. Reutova EV, Laktionov KP, Breder VV, Sarantseva KA, Okruzhnova MA, Peregudova MV. Immune-mediated adverse events associated with immune checkpoint inhibitors therapy. Zlokachestvenyye opukholi = Malignant tumours Journal. 2016; 4:68-76. (In Russ.) doi:10.18027/2224-5057-2016-4-68-76
3. Kostine M, Cappelli LC, Calabrese C, et al. Addressing immunerelated adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis. 2019; 78(6):860-862. doi:10.1136/annrheumdis-2018-214748
4. Bilbao LS, González-Mazón I, Martín-Varillas JL, et al. Immune-related adverse events associated with immunotherapy. Long-term follow-up of 102 patients from a referral single center. Ann Rheum Dis. 2019;78(2):1002. doi:10.1136/annrheumdis-2019-eular.7141
5. Cappelli LC, Shah AA, Bingham CO. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheum Dis Clin North Amer. 2017; 43(1):65-78. doi:10.1016/j.rdc.2016.09.007
6. Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immunerelated adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017; 3(1):1–5. doi:10.1136/rmdopen-2016-000412
7. Nasonov EL. Iimmune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2018; 56(1):5-9. (In Russ.). doi:10.14412/1995-4484-2018-5-9
8. Dhenin A, Samartzi V, Lejeune S, et al. Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ. 2019; 12(6):1–7. doi:10.1136/bcr-2018-229149
9. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis Rheumatol. 2017; 69(4):687-699. doi:10.1002/art.40043
10. Lepik KV. Immune Checkpoint Inhibitors in the Treatment of Lymphomas. Klinicheskaya onkogematologiya = Clinical Oncohematology Journal. 2018;11(4):303–312. (In Russ.). doi:10.21320/2500-2139-2018-11-4-303-312
11. Rapoport BL. Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors. Frontiers in Oncology. 2019;19(9):1–3. doi:10.3389/fonc.2019.00365
12. Wang C, Qiao W, Jiang Y, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Med. 2019;8(8):4023-4031. doi:10.1002/cam4.2280
13. Manolios N, Schrieber L. Checkpoint inhibitors and arthritis. Manolios N, Schrieber L. Checkpoint inhibitors and arthritis. Ann Rheum Dis. 2019;78(6):e58. doi:10.1136/annrheumdis-2018-213415
14. Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist. 2017;22(6):627-630. doi:10.1634/ theoncologist.2016-0390
15. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393-398. doi:10.1136/annrheumdis-2017-212257
16. Sapalidis K, Kosmidis C, Michalopoulos N, et al. Psoriatic arthritis due to nivolumab administration a case report and review of the literature. Respir Med Case Rep. 2018;23:182-187. doi:10.1016/j.rmcr.2018.03.001
17. Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer [published correction appears in Neurology. 2019;93(6):280]. Neurology. 2018;91(10):e985-e994. doi:10.1212/WNL.0000000000006124
18. Calabrese C, Cappelli LC, Kostine M, et al. Polymyalgia rheumatica-like syndrome fron checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open. 2019;5:e000906 doi:10.1136/rmdopen-2019-000906.
19. Kostine M, Richez C, Schaeverbeke T. Response to: ‘Druginduced lupus erythematosus following immunotherapy with antiprogrammed death-(ligand) 1’ by Michot et al and ‘Checkpoint inhibitor-associated immune arthritis’ by Arnaud et al. Ann Rheum Dis. 2019;78(7):69. doi:10.1136/annrheumdis-2018-213691
20. Tison A, Quere G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoinnune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100-2111. doi:10.1002/art.41068
21. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2019;5(9):1310-1317. doi:10.1001/jamaoncol.2019.1022
22. Judd J, Zibelman M, Handorf E, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. 2017;22(10):1232-1237. doi:10.1634/theoncologist.2017-0133
23. Gordon R, Kasler MK, Stasi K, et al. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management. Clin J Oncol Nurs. 2017;21(2):45-52. doi:10.1188/17.CJON.S2.45-52
24. Arnaud L, Lebrun-Vignes B, Salem J. Checkpoint inhibitorassociated immune arthritis. Ann Rheum Dis. 2019; 78(7):68. doi:10.1136/annrheumdis-2018-213470
Review
For citations:
Menshikova I.V., Strogonova V.V. Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors. Rheumatology Science and Practice. 2020;58(4):443-446. (In Russ.) https://doi.org/10.47360/1995-4484-2020-443-446
Views:
765
Email this article 